Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Schmidt-Hieber

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Biomedizinische Technik. Biomedical Engineering|September 18, 2013
Stimfit: A Fast Visualization and Analysis Environment for Cellular NeurophysiologyA Schlögl, P Jonas, C Schmidt-Hieber, et al.
Hematological Oncology|December 28, 2024
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin LymphomaH Moatti, P Brice, M-C Laroque, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Biomedizinische Technik. Biomedical Engineering|September 18, 2013
Stimfit: A Fast Visualization and Analysis Environment for Cellular NeurophysiologyA Schlögl, P Jonas, C Schmidt-Hieber, et al.
Hematological Oncology|December 28, 2024
One-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin LymphomaH Moatti, P Brice, M-C Laroque, et al.
Pageof 1